

Gout and a Subsequent Increased Risk of Erectile Dysfunction in Men Aged 64 and Under: A Nationwide Cohort Study in Taiwan

Yung-Fu Chen, Hsuan-Hung Lin, Chuan-Chin Lu, Chin-Tung Hung, Ming-Huei Lee, Chao-Yu Hsu, and Wei-Sheng Chung

ABSTRACT. Objective. Few studies have examined the relationship between gout and erectile dysfunction (ED). We investigated whether patients with gout exhibited an increased risk of ED.

Methods. This longitudinal nationwide cohort study investigated the incidence and risk of ED in 19,368 men with gout who were newly diagnosed between January 2002 and December 2008. A total of 77,472 controls without gout were randomly selected from the general population and frequency-matched according to age and sex. The patients were followed up from the date on which they were included in the study cohort to the date of an ED event, censoring, or December 31, 2010. We conducted the Cox proportional hazard model to estimate the effects of gout on ED risk including age and comorbidities.

Results. The gout cohort exhibited a 1.21-fold adjusted HR of subsequent ED development compared with the non-gout cohort (95% CI 1.03–1.44). The incidence of ED increased with age in both cohorts and was higher among the patients in the gout cohort than among those in the non-gout cohort. Compared to the patients without gout and comorbidities, the patients with both gout and any type of comorbidity exhibited a 2.04-fold risk of developing ED (95% CI 1.63–2.57). Further, the patients with gout who had numerous comorbidities exhibited the dose-response effect in developing ED.

Conclusion. This nationwide cohort study revealed that ED risk is significantly higher in patients with gout than in the general population. (J Rheumatol First Release June 15 2015; doi:10.3899/jrheum.141105)

Key Indexing Terms:

GOUT

ERECTILE DYSFUNCTION

POPULATION-BASED COHORT STUDY

Gout, of which the global prevalence is about 0.08%, is the most common cause of inflammatory arthritis in men worldwide¹. Previous reports have focused on the pharmacological and nonpharmacological treatment of gout^{2,3,4}. Gout frequently coexists with diabetes and hypertension, and is often neglected as a genuine risk factor for vascular disease^{5,6}. Studies have demonstrated that gout is an independent risk factor for cardiovascular disease (CVD) and cerebrovascular disease^{7,8}.

Erectile dysfunction (ED) is defined as the failure to attain or maintain an adequate erection during sexual activity. It affects millions of men worldwide^{9,10,11} and constitutes one of the most prevalent sexual problems¹². The prevalence of ED is strongly correlated with age¹³. Feldman, *et al* used a self-administered questionnaire in the context of the Massachusetts male aging study and reported that ED affected about 40% of men at age 40; further, the prevalence increases to nearly 70% in men aged 70¹⁴. ED may cause low

From the Department of Healthcare Administration, and Department of Dental Technology and Materials Science, and Department of Management Information Systems, Central Taiwan University of Science and Technology; Department of Health Services Administration, China Medical University; Department of Physical Therapy, Hungkuang University, Taichung; Department of Urology, Feng Yuan Hospital, Ministry of Health and Welfare; Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, Taichung; Department of Rheumatology, Nantou Hospital, Ministry of Health and Welfare, Nantou; Department of Family Medicine, and Department of Medical Education, Puli Christian Hospital, Nantou, Taiwan.

Supported by Taichung Hospital, Ministry of Health and Welfare under grant no. FL1030505007-2 and Ministry of Science and Technology under grant no. MOST104-2622-H-166-001.

Y.F. Chen, PhD, Department of Healthcare Administration, and Department of Dental Technology and Materials Science, Central Taiwan University of Science and Technology, and Department of Health Services Administration, China Medical University; H.H. Lin, PhD, Department of

Management Information Systems, Central Taiwan University of Science and Technology; C.C. Lu, MD, Department of Rheumatology, Nantou Hospital, Ministry of Health and Welfare, and Department of Physical Therapy, Hungkuang University; C.T. Hung, PhD, Department of Healthcare Administration, Central Taiwan University of Science and Technology; M.H. Lee, MD, Department of Urology, Feng Yuan Hospital, Ministry of Health and Welfare; C.Y. Hsu, MD, PhD, Department of Family Medicine, and Department of Medical Education, Puli Christian Hospital; W.S. Chung, MD, PhD, Department of Healthcare Administration, Central Taiwan University of Science and Technology, and Department of Health Services Administration, China Medical University, and Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare.

Y.F. Chen and H.H. Lin contributed equally to this work.

Address correspondence to Dr. W.S. Chung, Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, No. 199, Section 1, San-Min Road, Taichung City 40343, Taiwan.

E-mail: chung.w53@msa.hinet.net

Accepted for publication April 21, 2015.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved.

self-esteem, performance anxiety, and marital discontent. However, older men with ED do not like to discuss it with their physicians; therefore, ED remains underdiagnosed and undertreated^{15,16}.

Various chronic medical illnesses, including diabetes, CVD, and depression, are related to ED^{17,18}. However, the relationship between gout and ED is not clear. Therefore, we investigated the causal association between gout and the development of ED in Taiwan. The results were obtained from a nationwide retrospective cohort study assessing the possibility that the risk of ED is increased among patients with gout.

MATERIALS AND METHODS

Data sources. The National Health Insurance (NHI) program in Taiwan is a single-payer, compulsory insurance system that was established in 1995 by the Bureau of National Health Insurance (BNHI), Ministry of Health and Welfare. The insurance program provides healthcare to 99% of the 23.74 million citizens of Taiwan and maintains contracts with 97% of the nation's healthcare institutions¹⁹. The National Health Research Institute is authorized to establish the NHI Research Database (NHIRD), as well as to manage registration and claim data for the 23 million insured citizens. The current study used a subset of the NHIRD that consisted of 1 million randomly sampled beneficiaries enrolled in the NHI program. All of the NHI datasets can be interlinked through the de-identification of people; thus, NHI reimbursement data are suitable for public academic research. Each NHI dataset includes information on medical facility registries, inpatient orders, ambulatory care, dental services, prescription drugs, and physicians providing services as well as registration files containing encrypted identification data. Diagnoses are coded according to the International Classification of Diseases, 9th ed, Clinical Modification (ICD-9-CM). The high accuracy and validity of ICD-9-CM diagnoses in the NHIRD have been described in previous studies^{20,21}. This cohort study was approved by the Ethics Review Board of China Medical University Hospital (CTU 103-1/CMUH 103-REC1-088).

Study patients. We included in the gout cohort men aged 18 to 64 years with gout (ICD-9-CM Code 274) who were newly diagnosed by physicians between January 2002 and December 2008. The date of gout diagnosis was used as the index date. We excluded patients with a history of gout or ED preceding the index date. The comparison cohort was composed of randomly selected patients with no history of gout or ED, and these patients were frequency-matched with the patients with gout according to sex, age, and index date. Four people were assigned to the comparison cohort for each patient with gout.

Outcome measures. In general, the primary outcome was newly diagnosed ED (ICD-9-CM Code 607.84) that was identified by the urologists or physicians of internal or family medicine based on the patient's medical record, recent symptoms, scores of the Sexual Health Inventory for Men (SHIM) questionnaire, physical examination, and laboratory studies. The followup person-years were determined by calculating the interval between the index date and the date on which any of the following events occurred: the date of ED diagnosis, the date of withdrawal from the NHI program, the date of death, or December 31, 2011.

Covariates and comorbid diseases. The patients were stratified according to age into the following groups: ≤ 34 years, 35–44 years, 45–54 years, and 55–64 years. The comorbidities included in our study were diabetes (ICD-9-CM Code 250), congestive heart failure (ICD-9-CM Code 428), ischemic heart disease (ICD-9 Codes 410–414), hypertension (ICD-9 Codes 401–405), depression (ICD-9-CM Codes 296.2, 296.3, 300.4, 311), and chronic renal failure (ICD-9 Code 585). Further, we incorporated urate-lowering agents, including allopurinol, probenecid, benzbromarone, sulfipyrazone, and febuxostat, into consideration for

investigating the effect of urate-lowering therapy (ULT) on the development of ED.

Statistical analysis. All statistical analyses were performed using SPSS 17.0 software (SPSS Inc.). Differences in the proportional distribution of the demographic characteristics and comorbidities of the patients with gout and patients without gout were compared and tested using the chi-square test. The mean ages of both cohorts were measured and tested using the Student *t* test. The followup person-years were used to estimate the incidence density of ED. The incidence density rates of ED for the incidence rate ratios (IRR) of the gout cohort to the non-gout cohort and 95% CI were calculated based on the demographic statuses and comorbidities of the patients. The IRR were determined using the Poisson assumption. We assessed the overall, age-specific, and comorbidity-specific incidence of ED in both the gout and non-gout cohorts, and used Cox proportional hazard regression analysis to estimate the HR with 95% CI of ED development in the gout cohort and compared the results with those of the non-gout cohort. In addition, we measured the incidence and the HR for the interaction between gout and comorbidities on ED development. To assess the difference in the ED-free rates between the 2 cohorts, we applied Kaplan-Meier analysis and the log-rank test. All of the tests were performed at a 2-tailed significance level of 0.05.

RESULTS

Demographic characteristics and comorbidities of the patients with gout and people without gout. The gout cohort was composed of 19,368 patients and the comparison cohort was composed of 77,472 people without gout. The age distributions of the patients in the 2 cohorts were the same. The mean age of the patients in both cohorts were 42.7 ± 12.0 years. The prevalence of comorbid diseases, such as diabetes (11.2% vs 7.1%), ischemic heart disease (6.7% vs 4.1%), congestive heart failure (1.1% vs 0.6%), hypertension (25.5% vs 13.0%), and chronic renal failure (1.0% vs 0.6%), was significantly higher in the gout cohort than in the comparison cohort (Table 1).

For patients without ED, the patients with gout had a significantly greater number of physician visits than did the non-gout cohort (21.9 ± 19.6 vs 16.5 ± 16.9 , $p < 0.001$); whereas, for patients diagnosed with ED, the number of physician visits for the patients with gout was not significantly different from that of the non-gout cohort (49.7 ± 40.2 vs 51.0 ± 72.0 visits per person-yrs, $p = 0.816$). Further, the number of ED diagnoses made by the urologists was not significantly different between the patients with gout and the non-gout cohort (80.6% vs 82.4%, $p = 0.582$).

Comparison of the incidence and HR of ED between the gout cohort and the comparison cohort. The objective of our study was to investigate the effect of gout on the development of ED. In this causal study, it was found that, compared with the patients without gout, the patients with gout exhibited a higher incidence rate of ED (12.36 vs 9.07 per 10,000 person-yrs, $p < 0.001$), and the adjusted HR was 1.21 (95% CI 1.03–1.44, $p < 0.001$) after we controlled for age and comorbidities. The incidence rates of ED increased with age in both cohorts. The unadjusted IRR of ED was used to compare the patients with gout with the non-gout cohorts based on individual age strata. On the other hand, the adjusted

Table 1. Demographic characteristics and comorbidities in patients with and without gout. Data measured by chi-square test.

Variable	Gout		p
	No, n = 77,472	Yes, n = 19,368	
Age, yrs, n (%)			1.00
≤ 34	20,856 (26.9)	5214 (26.9)	
35–44	20,276 (26.2)	5069 (26.2)	
45–54	21,860 (28.2)	5465 (28.2)	
55–64	14,480 (18.7)	3620 (18.7)	
Age, mean (SD)*	42.7 (12.0)	42.7 (12.0)	1.00
Comorbidity, n (%)	15,218 (19.6)	6689 (34.5)	
Diabetes	5473 (7.1)	2164 (11.2)	< 0.001
Ischemic heart disease	3154 (4.1)	1291 (6.7)	< 0.001
Congestive heart failure	498 (0.6)	216 (1.1)	< 0.001
Hypertension	10,069 (13.0)	4935 (25.5)	< 0.001
Depression	1412 (1.8)	365 (1.9)	< 0.571
Chronic renal failure	470 (0.6)	200 (1.0)	< 0.001
Physician visit, per person-years			
No ED diagnosed, mean (SD)*	16.5 (16.9)	21.9 (19.6)	< 0.001
With ED diagnosed, mean (SD)*	51.0 (72.0)	49.7 (40.2)	0.816
Specialist making ED diagnosis, no. events (%)			0.582
Urologist	460 (82.4)	150 (80.6)	
Non-urologist	98 (17.6)	36 (19.4)	

* Measured by 2 sample Student t tests. ED: erectile dysfunction.

HR of the successive age strata shown in Table 2 were obtained by taking the whole cohort into consideration in the full model with the aged ≤ 34 group treated as the reference. As shown in the table, the incidence rate of ED was significantly higher in the gout cohort than in the non-gout cohort. After we adjusted for covariates, the risk of ED was the highest in the group of patients aged 55–64 years, and the adjusted HR was 5.68 (95% CI 4.17–7.73) compared with the

group of patients ≤ 34 years of age. The adjusted HR increased with age, which was consistent with the observation reported in previous investigations^{13,14}. Patients with 1 or more comorbidities exhibited a higher incidence rate of ED than did those without any comorbidity in both cohorts. After we adjusted for covariates, the patients with any type of comorbidities exhibited a 1.79-fold increased risk of ED compared with those with no comorbidity (95% CI 1.53–2.09).

Table 2. Comparison of incidence rate and HR of ED stratified by age and comorbidity between patients with and without gout.

Variables	Gout						IRR*(95% CI)	Adjusted HR† (95% CI)
	No			Yes				
	Event, n	Person-years	Rate#	Event, n	Person-years	Rate#		
All	558	615,265	9.07	186	150,528	12.36	1.35 (1.14–1.59)***	1.21 (1.03–1.44)*
Age								
≤ 34	36	167,808	2.15	16	41,224	3.88	1.79 (0.99–3.23)	1 (reference)
35–44	108	163,249	6.62	33	39,866	8.28	1.25 (0.85–1.84)	2.59 (1.88–3.56)***
45–54	216	172,700	12.51	72	42,298	17.02	1.35 (1.03–1.76)*	4.48 (3.32–6.05)***
55–64	198	111,508	17.76	65	27,140	23.95	1.33 (1.00–1.76)*	5.68 (4.17–7.73)***
Comorbidity‡								
No	329	497,796	6.61	87	99,955	8.70	1.31 (1.04–1.67)*	1 (reference)
Yes, any	229	117,469	19.49	99	50,573	19.58	1.00 (0.78–1.25)	1.79 (1.53–2.09)***
Diabetes	102	41,979	24.30	39	16,374	23.82	0.97 (0.67–1.41)	
Ischemic heart disease	50	24,533	20.38	36	9905	36.35	1.06 (1.01–1.11)**	
Congestive heart failure	9	3777	23.83	0	1632	0	0.03 (0–10.92)	
Hypertension	144	77,679	18.54	64	37,224	17.19	0.99 (0.96–1.02)	
Depression	28	10,814	25.89	10	2697	37.08	1.40 (0.68–2.89)	
Chronic renal failure	6	3562	16.84	2	1496	13.37	0.78 (0.16–3.88)	

Incidence rate, per 10,000 person-years. † Multivariable analysis including age, gout, and comorbidity. ‡ Any 1 of comorbidities classified patient in the comorbidity group. * p < 0.05. ** p < 0.01. *** p < 0.001. ED: erectile dysfunction; IRR: incidence ratio rate.

Interaction on the risk of ED between gout and any comorbidity. The interaction measurements between gout and any comorbidity on the risk of ED are shown in Table 3. Compared with the patients without gout or comorbidity, the patients without gout but with comorbidities exhibited a 1.92-fold risk of developing ED (95% CI 1.61–2.30), and the highest risk was observed in patients with both gout and comorbidities (adjusted HR 2.04, 95% CI 1.63–2.57).

Association between the risk of ED and the number of comorbidities. Table 4 lists the incidence and risk of ED in patients with or without gout accompanied with various numbers of comorbidities. The patients with a different number of comorbidities exhibited a dose response effect of ED development compared to the non-gout participants with no comorbidity. Compared with the patients without gout and without comorbidity, the adjusted HR of increasing number of comorbidities increased in both cohorts (Table 4). For patients without comorbidity or with 2 or more comorbidities, the crude HR and adjusted HR of patients with gout were both higher than patients without gout.

Additionally, compared with the patients without gout with no comorbidity, the HR of developing ED remained greater in the patients with gout without comorbidity receiving fewer than 90 days of ULT (adjusted HR 1.41, 95% CI 1.11–1.79), but reached no significant difference in those

who received 90 days or more of ULT (adjusted HR 0.88, 95% CI 0.12–6.27).

Probability of ED in the gout and non-gout cohorts during followup. Figure 1 shows the Kaplan-Meier curve of ED for the patients with gout and those without gout, in which the Y axis indicates the accumulated probability of acquired ED as a function of time (in years) after gout being diagnosed until ED occurred. The results indicated that the cumulative probability of ED was significantly greater in the patients with gout than in those in the non-gout cohort (log rank $p < 0.0001$).

DISCUSSION

Most previous studies focused on cross-sectional investigations of the association between gout and ED^{22,23}. It was reported that men with gout were more likely to have ED than men without gout by using self-reported questionnaires (76% vs 52%, $p < 0.001$)²² and by reviewing patient medical history, physical examination results, and recent laboratory studies accompanied by the filled SHIM questionnaire (39.8% vs 28.8%, $p < 0.001$)²³ in the context of a US community-based study. Schlesinger, *et al*²³ showed that after adjusting for age and comorbidities, including hypertension, low-density lipoprotein, diabetes, depression, obesity, and chronic kidney disease, gout was still significantly associated with ED. To our knowledge, to date no causal study regarding

Table 3. Cox proportional hazards regression analysis for interaction of gout and comorbidity on risk of ED.

Gout	Comorbidity [‡]	Person-years	Event, n	Rate [#]	HR (95% CI)		p < 0.001
					Crude	Adjusted [†]	
No	No	497,796	329	6.61	1 (Reference)	1 (Reference)	
No	Yes	117,469	229	19.49	2.93 (2.48–3.47)***	1.92 (1.61–2.30)***	
Yes	No	99,955	87	8.70	1.31 (1.04–1.66)*	1.40 (1.11–1.77)**	
Yes	Yes	50,573	99	19.58	2.89 (2.31–3.62)***	2.04 (1.63–2.57)***	

[‡] Patients with any 1 of the comorbidities (diabetes, ischemic heart disease, congestive heart failure, hypertension, depression, and chronic renal disease) were classified as the comorbidity group. [#] Incidence rate, per 10,000 person-years. [†] Multivariable analysis including age, gout, and comorbidity (note: patients with any 1 of the comorbidities were classified as the comorbidity group). * $p < 0.05$. ** $p < 0.01$. *** $p < 0.001$. ED: erectile dysfunction.

Table 4. HR and 95% CI of ED risk associated with the ULT and the number of comorbidities.

Variables	ED Cases, n	HR (95% CI)	
		Crude	Adjusted [†]
Non-gout with no. comorbidities			
0, n = 62,332	329	1 (Reference)	1 (Reference)
1, n = 10,533	146	2.70 (2.22–3.28)***	1.84 (1.51–2.25)***
≥ 2, n = 4607	83	3.45 (2.71–4.38)***	2.11 (1.64–2.70)***
Gout with no. comorbidities			
0, received < 90 days of ULT, n = 12,474	86	1.32 (1.04–1.68)*	1.41 (1.11–1.79)**
0, received ≥ 90 days of ULT, n = 234	1	0.85 (0.12–6.06)	0.88 (0.12–6.27)
1, n = 4729	57	2.37 (1.79–3.14)***	1.73 (1.31–2.31)***
≥ 2, n = 1931	42	4.15 (3.01–5.72)***	2.66 (1.91–3.68)***

[†] Multivariable analysis including age, gout, and comorbidity (note: comorbidity was divided into 3 categories including no comorbidity, 1 comorbidity, and ≥ 2 comorbidities). * $p < 0.05$. ** $p < 0.01$. *** $p < 0.001$. ED: erectile dysfunction; ULT: urate-lowering therapy.




Figure 1. Kaplan-Meier analysis comparing probabilities of ED between patients with gout and non-gout cohort. ED: erectile dysfunction.

the association between gout and ED has been conducted. This is the first study to investigate the effect of gout on the risk of subsequent ED in an Asian population by using a nationwide cohort study. The study determined that patients with gout exhibited a 1.21-fold greater risk of ED development than did the non-gout comparison cohort. Previous studies have also indicated that the detrimental health effects of gout include an increased risk of cardiovascular and cerebrovascular events^{7,24,25}.

As indicated in Table 2, among the patients with comorbidity, the incidence rate of ED in patients without gout (19.49 per 10,000 person-yrs) was similar to those with gout (19.58 per 10,000 person-yrs). The IRR of 1.00 (95% CI 0.78–1.25) indicates that comorbidities may dilute the influence of gout on ED. However, among those without comorbidities, the risk of ED for patients with gout was significantly higher than for those without gout with an IRR of 1.31 (95% CI 1.04–1.67), suggesting that gout might be an independent factor increasing the risk of ED. As presented in Table 3, the incidence rate of ED for patients who had no gout but had 1 or more comorbidities (19.49 per 10,000 person-yrs) was much higher than those who had gout but without comorbidities (8.7 per 10,000 person-yrs). However, the former cases were entangled with multiple factors, (i.e., 1 or more comorbidities) while in the latter, only 1 single factor had been involved (i.e., gout). Moreover, the incidence rate of ED for patients who had gout but without comorbidities was significantly higher than for those with neither gout nor comorbidity (8.7 vs 6.61 per 10,000 person-yrs) with an adjusted HR of 1.40 (95% CI 1.11–1.77). The patients with gout with 1 or more comorbidities had a 2.04-fold increased risk of ED compared with that of the non-gout cohort that did not have any comorbidities (Table 3). Again,

these data indicate that gout is an independent factor in predicting the ED development.

The direction of causality in the relationship between gout and ED is not clear. The pathogenic mechanisms of gout indicate an inflammatory response that may contribute to vascular effects²⁶. Inflammation may induce endothelial dysfunction and evolve into arteriosclerosis^{27,28}. In addition, the inflammatory process can cause clotting, thereby reducing the activity of natural anticoagulant mechanisms and impairing the fibrinolytic system^{29,30}. The comorbidities associated with gout include hypertension, diabetes, obesity, and chronic kidney diseases, all of which are associated with similar risks with vascular diseases³¹. The pathophysiological mechanisms of ED can be classified into 4 types: psychogenic, neurogenic, endocrinologic, and arteriogenic mechanisms³². Table 5 lists the pathophysiological mechanisms of ED associated with gout^{27,28,29,30} and other comorbidities, including diabetes¹⁷, ischemic heart disease^{33,34}, congestive heart failure^{35,36}, hypertension^{37,38}, depression¹⁸, and chronic renal failure³⁹.

The incidence of ED increased with age in both cohorts, exhibiting an especially marked increase after the age of 45; this result is consistent with those reported in previous studies^{40,41,42,43}. In the population-based cohort studies of US citizens and Brazilians, it was observed that the incidence rates of ED in men 40 to 90 years old were 259 and 656 cases per 10,000 person-years, respectively^{40,43}. In our population-based cohort study, the incidence rate of ED in men 18 to 64 years old without gout was only 9.07 cases per 10,000 person-years, which is much lower than the US and Brazilian populations. The difference of ED incidence between our study and the Western study might be associated with various races and age study groups. Biological aging causes older

Table 5. Pathophysiological mechanism of erectile dysfunction associated with gout and other comorbid diseases.

Disease	Mechanism
Gout ^{27,28,29,30}	Arteriogenic: Inflammation-induced endothelial dysfunction, arteriosclerosis, and clotting
Diabetes ³³	Arteriogenic: Endothelial dysfunction for relaxing smooth muscle, penile artery atherosclerosis, chronic inflammation Neurogenic: Autonomic neuropathy Endocrinologic: Hypogonadism
Ischemic heart failure ^{34,35}	Arteriogenic: Endothelial dysfunction (induced penile artery atherosclerosis and flow-limiting stenosis); higher level of inflammation mediators.
Congestive heart failure ^{36,37}	Psychogenic: Depression, anxiety, and fear in decreasing libido and increasing sympathetic tone Arteriogenic: Atherosclerosis, endothelial dysfunction, impaired endothelial-independent vasodilation
Hypertension ^{38,39}	Arteriogenic: Endothelial dysfunction and atherosclerosis (leading to structural changes of the arterial and erectile tissue, as well as reduction of NO secretion); higher level of inflammation mediators
Depression ⁴⁰	Psychogenic: Decreased libido, increased sympathetic tone
Chronic renal failure ⁴¹	Endocrinologic: Hypogonadism and hyperthyroidism Neurogenic: Autonomic neuropathy Arteriogenic: Endothelial dysfunction, anemia, and erythropoietin deficiency

men to be more likely to have comorbid conditions than younger men. In addition to the aging process, reduced physical activity among older men may increase the risk of ED^{41,44}.

Men with comorbid diseases exhibited a 1.79-fold greater risk of ED than did those who did not have comorbidities (Table 2). Previous reports have indicated that the prevalence of ED is positively associated with cardiovascular risk factors such as diabetes and heart diseases^{45,46}. Ischemic heart disease and ED are frequently comorbid and share common risk factors, including age, hypertension, and diabetes. The patients with gout who had any type of comorbid condition exhibited a multiplicative risk of developing ED compared with those with no gout or comorbid diseases. Further, the patients with gout who had various comorbidities exhibited a dose-response effect on the development of ED. In addition, the cumulative rate of ED was significantly greater in the gout cohort than in the non-gout cohort. These results are relatively robust because several multivariable model analyses were used to assess the increased risk of ED development.

Compared with non-gout with no comorbidity, the patients with gout without comorbidity receiving fewer than 90 days of ULT remained at a greater risk of ED. On the other hand, the patients with gout without comorbidity receiving 90 days or more of ULT reached no significant difference of ED risk compared with the non-gout cohort without comorbidity. This finding indicated that receiving ULT for more than 90 days may decrease the risk of ED development for patients with gout who had no comorbidity. Because gout is deemed a chronic disease, physicians are allowed to prescribe the third consecutive refill medication for patients with chronic

diseases, according to the regulations of the NHI Bureau of Taiwan. Patients have to visit their physicians again for tracking of the disease progression and for additional consecutive prescriptions. It is assumed that patients with gout who have received more than 1 continuous medication prescription might have adhered to longterm treatments, resulting in better control of gout and a prevention of ED occurrence.

As listed below, several limitations must be considered when interpreting these findings:

(1) Lack of lifestyle information in NHIRD. Because patients with gout are more likely to have comorbidities, an increased risk of ED in patients with gout may be associated with comorbidities that were either not measured or comorbidities that were not recorded in the patient's records. For example, detailed lifestyle information, such as body mass index, physical activity levels, socioeconomic status, alcohol use, and smoking status, which could potentially confound the results of our study, are not provided in NHIRD.

(2) ED diagnosis based on clinic visits and physician diagnoses. Most Taiwanese are shy or ashamed to visit physicians for ED; thus, the actual incidence of ED may have been underestimated.

(3) Study cases selected based on ICD-9-CM codes. This potentially caused misclassification bias. However, the BNHI can audit the diagnosis and management codes by means of a peer review to minimize diagnostic uncertainty and misclassification.

(4) Patients having more physician visits might be more likely to be diagnosed with ED. The patients with gout or without gout who had been diagnosed with ED had a higher number of physician visits than did patients who had no ED (Table 1). However, the association between the number of

physician visits and probability of being diagnosed with ED is not clear, because other diseases or comorbidities may also increase the frequency of physician visits.

Our study is the first, to our knowledge, to provide epidemiologic data to address the relationship between gout and ED. The strength of our study lies in the use of a large sample size representing an Asian population to investigate the relationship. Each NHI beneficiary is assigned a unique personal identification number; therefore, every participant could be tracked in the NHIRD throughout the followup period. Moreover, the ED diagnoses were provided by physicians rather than self-reported by the patients.

Our nationwide population-based cohort study, which examined 19,368 patients with gout over a followup period of about 150,000 person-years, indicated that patients with gout are at a 1.21-fold greater risk of developing ED than the general population. These findings emphasize the importance of implementing a multidisciplinary approach to manage the potential risk factors contributing to the development of ED among patients with gout. Additional studies on the biological mechanisms of gout and its effect on the development of ED are warranted.

REFERENCES

1. Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. *Ann Rheum Dis* 2014;73:1470-6.
2. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al: American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res* 2012;64:1431-46.
3. Neogi T. Clinical practice. Gout. *N Engl J Med* 2011;364:443-52.
4. Roddy E, Doherty M. Treatment of hyperuricaemia and gout. *Clin Med* 2013;13:400-3.
5. Choi HK, De Vera MA, Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. *Rheumatology* 2008;47:1567-70.
6. Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, Wagenknecht LE, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. *Hypertension* 2006;48:1037-42.
7. Kuo CF, Yu KH, See LC, Chou IJ, Ko YS, Chang HC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. *Rheumatology* 2013;52:111-7.
8. Seminog OO, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. *Rheumatology* 2013;52:2251-9.
9. Eid JF, Nehra A, Andersson KE, Heaton J, Lewis RW, Morales A, et al. First international conference on the management of erectile dysfunction. Overview consensus statement. *Int J Impot Res* 2000;12 Suppl 4:S2-5.
10. De Berardis G, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, et al; Quality of Care and Outcomes in Type 2 Diabetes (QuED) Study Group. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. *Diabetes Care* 2002;25:284-91.
11. Grant P, Jackson G, Baig I, Quin J. Erectile dysfunction in general medicine. *Clin Med* 2013;13:136-40.
12. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muirheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. *N Engl J Med* 2007;357:762-74.
13. McVary KT. Clinical practice. Erectile dysfunction. *N Engl J Med* 2007;357:2472-81.
14. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. *J Urol* 1994;151:54-61.
15. Ellsworth P, Kirshenbaum EM. Current concepts in the evaluation and management of erectile dysfunction. *Urol Nurs* 2008; 28:357-69.
16. Gareri P, Castagna A, Francomano D, Cerminara G, De Fazio P. Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives. *Int J Endocrinol* 2014;2014:878670.
17. Weinberg AE, Eisenberg M, Patel CJ, Chertow GM, Leppert JT. Diabetes severity, metabolic syndrome, and the risk of erectile dysfunction. *J Sex Med* 2013;10:3102-9.
18. Roose SP. Depression: links with ischemic heart disease and erectile dysfunction. *J Clin Psychiatry* 2003;64 Suppl 10:26-30.
19. Cheng TM. Taiwan's National Health Insurance system: high value for the dollar. In: Okma KG, Crivelli L, editors. Six countries, six reform models: the health reform experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan. New Jersey: World Scientific; 2009:71-204.
20. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. *Pharmacoepidemiol Drug Saf* 2011;20:236-42.
21. Chung WS, Lin CL, Peng CL, Chen YF, Lu CC, Sung FC, et al. Rheumatoid arthritis and risk of acute myocardial infarction—a nationwide retrospective cohort study. *Int J Cardiol* 2013; 168:4750-4.
22. Maynard W, McAdams JA, Baer MN, Hoffman-Bolton A, Gelber JC, Josef AC. Erectile dysfunction is associated with gout in the campaign against cancer and heart disease (CLUE II). *Arthritis Rheum* 2010;62 Suppl 10:1544.
23. Schlesinger N, Radvanski DC, Fischkoff J, Kostis JB. Erectile dysfunction is common among gout patients. *Ann Rheum Dis* 2014;73 Suppl 2:111-2.
24. Kok VC, Horng JT, Lin HL, Chen YC, Chen YJ, Cheng KF. Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan. *BMC Cardiovasc Disord* 2012;12:108.
25. Lin YH, Hsu HL, Huang YC, Lee M, Huang WY, Huang YC, et al. Gouty arthritis in acute cerebrovascular disease. *Cerebrovasc Dis* 2009;28:391-6.
26. Jin M, Yang F, Yang I, Ying Y, Luo JJ, Wang H, et al. Uric acid, hyperuricemia and vascular diseases. *Front Biosci* 2012;17:656-69.
27. Galle J, Quaschnig T, Seibold S, Wanner C. Endothelial dysfunction and inflammation: what is the link? *Kidney Int Suppl* 2003;63:S45-9.
28. Clapp BR, Hirschfield GM, Storry C, Gallimore JR, Stidwill RP, Singer M, et al. Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. *Circulation* 2005;111:1530-6.
29. Levi M, van der Poll T, Büller HR. Bidirectional relation between inflammation and coagulation. *Circulation* 2004;109:2698-704.
30. Esmon CT. The interactions between inflammation and coagulation. *Br J Haematol* 2005;131:417-30.
31. Edwards NL. The role of hyperuricemia in vascular disorders. *Curr Opin Rheumatol* 2009;21:132-7.
32. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. *Urol Clin North Am* 2005;32:379-95.
33. Pohnholzer A, Temml C, Obermayr R, Wehrberger C, Madersbacher S. Is erectile dysfunction an indicator for increased risk of coronary

- heart disease and stroke? *Eur Urol* 2005;48:512-8.
34. Jackson G, Boon N, Eardley I, Kirby M, Dean J, Hackett G, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. *Int J Clin Pract* 2010;64:848-57.
 35. Jaarsma T, Dracup K, Walden J, Stevenson LW. Sexual function in patients with advanced heart failure. *Heart Lung* 1996;25:262-70.
 36. Schwarz ER, Rastogi S, Kapur V, Sulemanjee N, Rodriguez JJ. Erectile dysfunction in heart failure patients. *J Am Coll Cardiol* 2006;48:1111-9.
 37. Jeremy JY, Angelini GD, Khan M, Mikhailidis DP, Morgan RJ, Thompson CS, et al. Platelets, oxidant stress and erectile dysfunction: an hypothesis. *Cardiovasc Res* 2000;46:50-4.
 38. Gandaglia G, Briganti A, Jackson G, Kloner RA, Montorsi F, Montorsi P, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. *Eur Urol* 2014;65:968-78.
 39. Suzuki E, Nishimatsu H, Oba S, Takahashi M, Homma Y. Chronic kidney disease and erectile dysfunction. *World J Nephrol* 2014;3:220-9.
 40. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. *J Urol* 2000;163:460-3.
 41. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. *Ann Intern Med* 2003;139:161-8.
 42. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. *Am J Med* 2007;120:151-7.
 43. Moreira ED Jr, Lbo CF, Diament A, Nicolosi A, Glasser DB. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. *Urology* 2003;61:431-6.
 44. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. A prospective study of risk factors for erectile dysfunction. *J Urol* 2006;176:217-21.
 45. Ahn TY, Park JK, Lee SW, Hong JH, Park NC, Kim JJ, et al. Prevalence and risk factors for erectile dysfunction in Korean men: results of an epidemiological study. *J Sex Med* 2007;4:1269-76.
 46. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). *Am J Cardiol* 2005;96:313-21.